EZH2 Inhibitors Archives

Epizyme’s Tazverik Picks Up Its Second FDA Approval of 2020

Accelerated Review, Adults, Approvals, EZH2 Inhibitors, FDA/Regulatory, Follicular Lymphoma, New Indications, Priority Review, Stocks, Supplemental New Drug Application (sNDA)

Shares of Epizyme stock rose after the company’s first-in-class EZH2 inhibitor Tazverik won approval from the U.S. Food and Drug Administration for the second time in 2020.

June 19, 2020/by BioSpace

Epizyme Wins FDA Approval for Epithelioid Sarcoma Drug

Accelerated Review, Approvals, Epithelioid Sarcoma (ES), EZH2 Inhibitors, FDA, FDA/Regulatory, First-In-Class, INI1 Protein, Soft tissue

Epizyme’s oral potent, first-in-class EZH2 inhibitor tazemetostat won accelerated approval from the U.S. Food and Drug Administration for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

January 24, 2020/by BioSpace